T1	Outcomes 329 379	accelerated development of cardiovascular disease.
T2	Outcomes 543 558	LDL cholesterol
T3	Outcomes 1632 1677	change in ultracentrifugation LDL cholesterol
T4	Outcomes 2078 2121	reduced ultracentrifugation LDL cholesterol
T5	Outcomes 2172 2183	p<0Â·0001).
T6	Outcomes 2184 2210	Treatment-emergent adverse
T7	Outcomes 2379 2422	and no anti-evolocumab antibody development
T8	Outcomes 2648 2666	was well tolerated
T9	Outcomes 2685 2708	reduced LDL cholesterol
